Search

Your search keyword '"Arumugaswami V"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Arumugaswami V" Remove constraint Author: "Arumugaswami V"
105 results on '"Arumugaswami V"'

Search Results

2. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

4. Mpox Virus and its ocular surface manifestations.

5. Envelope protein-specific B cell receptors direct lentiviral vector tropism in vivo.

6. Harnessing Biomaterials to Amplify Immunity in Aged Mice through T Memory Stem Cells.

7. Targeting ABCG1 and SREBP-2 mediated cholesterol homeostasis ameliorates Zika virus-induced ocular pathology.

8. A ketogenic diet can mitigate SARS-CoV-2 induced systemic reprogramming and inflammation.

9. The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles.

10. Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus.

11. Comparative Analysis of Molecular Pathogenic Mechanisms and Antiviral Development Targeting Old and New World Hantaviruses.

12. Innate immune pathway modulator screen identifies STING pathway activation as a strategy to inhibit multiple families of arbo and respiratory viruses.

13. Low complexity domains of the nucleocapsid protein of SARS-CoV-2 form amyloid fibrils.

14. Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses.

15. Longitudinal Evaluation of Antibody Persistence in Mother-Infant Dyads After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy.

16. Differential Susceptibility of Fetal Retinal Pigment Epithelial Cells, hiPSC- Retinal Stem Cells, and Retinal Organoids to Zika Virus Infection.

17. Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response.

18. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.

19. Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model.

20. Importance of clitellar tissue in the regeneration ability of earthworm Eudrilus eugeniae.

21. Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models.

22. Draft Genome Sequence of the Earthworm Eudrilus eugeniae .

23. Identification, tissue specific expression analysis and functional characterization of arrestin gene (ARRDC) in the earthworm Eudrilus eugeniae: a molecular hypothesis behind worm photoreception.

24. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention.

25. Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection.

26. ORAI1 Limits SARS-CoV-2 Infection by Regulating Tonic Type I IFN Signaling.

27. SARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune response.

28. Neurological pathophysiology of SARS-CoV-2 and pandemic potential RNA viruses: a comparative analysis.

29. The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2.

30. A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry.

31. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition.

32. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro.

33. Comparative transcriptomic analysis of SARS-CoV-2 infected cell model systems reveals differential innate immune responses.

34. Structure-based design of antisense oligonucleotides that inhibit SARS-CoV-2 replication.

35. Development of a blocker of the universal phosphatidylserine- and phosphatidylethanolamine-dependent viral entry pathways.

36. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.

37. Deleterious Effects of SARS-CoV-2 Infection on Human Pancreatic Cells.

38. ORAI1 establishes resistance to SARS-CoV-2 infection by regulating tonic type I interferon signaling.

39. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery.

40. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.

41. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition.

42. Systemic diseases and the cornea.

43. ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response.

44. Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity.

45. The transcriptome of anterior regeneration in earthworm Eudrilus eugeniae.

46. Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases Infection Severity and Alters the Stem Cell-Derived Airway Repair Response.

47. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro .

48. Cold atmospheric plasma for SARS-CoV-2 inactivation.

49. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection.

50. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery.

Catalog

Books, media, physical & digital resources